This Article  • Full text  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (65)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Viral Infections  • Otolaryngology/ Head & Neck Surgery  • Endocrine Disease of Head & Neck  • Thyroid/ Parathyroid Diseases  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

Luisa Fernandez-Soto, MD, PhD; Amalia Gonzalez, MD, PhD; Fernando Escobar-Jimenez, MD, PhD; Rafael Vazquez, MD; Esther Ocete, MD, PhD; Nicolas Olea, MD, PhD; Javier Salmeron, MD, PhD

Arch Intern Med. 1998;158:1445-1448.

Background  Thyroid gland dysfunction has been reported to occur with variable frequency during interferon alfa (IFN-) therapy in patients with the hepatitis C virus (HCV). We prospectively evaluated if the prevalence of autoimmune thyroid disease in patients with HCV differs from that in patients with the hepatitis B virus (HBV) before, at the end of, and 6 months after stopping treatment with IFN-.

Methods  One hundred thirty-four patients with HCV and 41 patients with HBV were studied. Measurements of serum free thyroxine, free triiodothyronine, thyrotropin, thyroid peroxidase antibodies (TPOAbs), thyroglobulin antibodies (TgAbs), and thyrotropin-binding inhibitory immunoglobulin were performed.

Results  Positive levels of TPOAb and TgAb were found in 20% and 11% of patients with HCV compared with 5% and 3% of patients with HBV, respectively. At the end of IFN- therapy, thyroid gland dysfunction was more prevalent in patients with HCV (12%) compared with those with HBV (3%), with thyrotropin levels significantly higher in the HCV group (P=.03). Titers of TPOAb, TgAb, and thyrotropin-binding inhibitory immunoglobulin increased significantly (P=.02, P=.04, and P=.02, respectively) at the end of IFN- therapy in patients with HCV but not in those with HBV. Patients who developed thyroid gland dysfunction were predominantly female (P=.03), had decreased levels of free triiodothyronine (P<.001), and had a higher prevalence of TPOAb (P=.03) before treatment with IFN-. Thyroid gland dysfunction was reversed in 60% of those with HCV 6 months after discontinuing treatment with IFN-.

Conclusions  Patients with HCV are more susceptible than patients with HBV to autoimmune thyroid disease. Systematic screening of thyroid gland function and TPOAb titers in all patients with HCV before, during, and after IFN- therapy appears warranted. This precaution is not necessary for patients with HBV.

From the Endocrine and Metabolic Unit (Drs Fernandez-Soto, Gonzalez, Escobar-Jimenez, and Vazquez), the Departments of Pediatrics (Dr Ocete) and Radioisotopes (Dr Olea), and the Digestive Unit (Dr Salmeron), Universitary Hospital, Granada, Spain.

RELATED LETTER

The Uncertain Natural History of Thyrotoxic Patients Treated With Combination Interferon Alfa-2 and Ribavirin—Reply
Saurabh Mehandru and Edmund J. Bini
Arch Intern Med. 2005;165(9):1072-1073.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-{alpha} therapy for hepatitis C virus-related hepatitis
Rotondi et al.
Eur J Endocrinol 2007;156:409-414.
ABSTRACT | FULL TEXT  

The Uncertain Natural History of Thyrotoxic Patients Treated With Combination Interferon Alfa-2{beta} and Ribavirin--Reply
Mehandru and Bini
Arch Intern Med 2005;165:1072-1073.
FULL TEXT  

Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C: A Prospective Cohort Study
Bini and Mehandru
Arch Intern Med 2004;164:2371-2376.
ABSTRACT | FULL TEXT  

Interferon-{alpha}-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects
Carella et al.
J. Clin. Endocrinol. Metab. 2004;89:3656-3661.
FULL TEXT  

Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia
Antonelli et al.
QJM 2004;97:499-506.
ABSTRACT | FULL TEXT  

Interferon alpha treatment and endocrine disease
Chan et al.
JRSM 2003;96:481-485.
FULL TEXT  

Hepatitis B virus: old, new and future approaches to antiviral treatment
Karayiannis
J Antimicrob Chemother 2003;51:761-785.
ABSTRACT | FULL TEXT  

Personal Health Records: Evaluation of Functionality and Utility
Kim and Johnson
J. Am. Med. Inform. Assoc. 2002;9:171-180.
ABSTRACT | FULL TEXT  

Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient
Pouthier et al.
Nephrol Dial Transplant 2002;17:174-174.
FULL TEXT  

Thyroid Function and Autoimmunity during Interferon {beta}-1b Treatment: A Multicenter Prospective Study
Durelli et al.
J. Clin. Endocrinol. Metab. 2001;86:3525-3532.
ABSTRACT | FULL TEXT  

Long-Term Outcome of Interferon-{{alpha}}-Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment
Carella et al.
J. Clin. Endocrinol. Metab. 2001;86:1925-1929.
ABSTRACT | FULL TEXT  

Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C
Wesche et al.
Gut 2001;48:378-383.
ABSTRACT | FULL TEXT  

Thyroid Cancer in Patients With Hepatitis C Infection
Antonelli et al.
JAMA 1999;281:1588-1588.
FULL TEXT